Skip to main content
60°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
222.39
-2.95 (-1.31%)
Streaming Delayed Price
Updated: 10:48 AM EDT, May 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
42
43
Next >
CEO Climate Alliance to World Leaders: We Support You in Taking Decisive Climate Steps at COP26
November 11, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Emissions
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition....
Via
Benzinga
This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
November 09, 2021
Photo by Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...
Via
Benzinga
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
November 06, 2021
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...
Via
Talk Markets
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Exposures
COVID-19
Introducing Biogen's 2021 Diversity, Equity & Inclusion Report
November 04, 2021
SOURCE: Biogen
Via
3BL Media
Expert Ratings For Biogen
October 26, 2021
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) with...
Via
Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
Biogen Launches Supplier Climate Action Program “Energize” With Leading Pharmaceutical Companies
November 04, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Climate Change
Supply Chain
Exposures
Climate
Supply Chain
MSM Students to Participate in Biogen's Summer Health Equity Fellowship Program
October 26, 2021
SOURCE: Biogen
Via
3BL Media
Analyst Ratings For Biogen
October 21, 2021
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) with...
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
A Letter From Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis Is a Health Crisis
November 03, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Climate Change
Death
Emissions
Exposures
Climate
Death
Supply Chain
Healthcare Stocks Subject to Government Policy
November 02, 2021
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
MIT Collaborates With Biogen on Three-Year, $7 Million Initiative to Address Climate, Health, and Equity
November 01, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Climate Change
Exposures
Climate
Cassava Stock Could Jump More Than 200 Times
November 01, 2021
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock.
Via
InvestorPlace
Biogen Beat Earnings and Raised Guidance. Here's Why I Still Wouldn't Buy the Stock
October 29, 2021
Aduhelm remains a big question mark for the company.
Via
The Motley Fool
Will Chart Analysts Notice Bad Omen on Biogen's Chart
October 29, 2021
If history is any guide, there may be trouble ahead for shares of Biogen (NASDAQ:BIIB). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Should Biogen Investors Be Preparing for the Worst?
October 27, 2021
With sagging sales and lackluster data in a recent trial, what does the future hold for shareholders?
Via
The Motley Fool
Why This Alzheimer's Study Missed, But That's Not Necessarily A Bad Thing For Cortexyme
October 26, 2021
Cortexyme said Tuesday its experimental Alzheimer's drug might work in some patients.
Via
Investor's Business Daily
10 Biggest Price Target Changes For Tuesday
October 26, 2021
Berenberg cut Kimberly-Clark Corporation (NYSE:KMB)...
Via
Benzinga
3 Big Problems With Biogen's Q3 Results
October 23, 2021
Sure, Biogen beat analysts' estimates in Q3. But the company still has some serious challenges.
Via
The Motley Fool
Athira CEO Resigns After Data Manipulation Firestorm, But Alzheimer's Stock Pops
October 22, 2021
Athira CEO Leen Kawas resigned after an investigation found she altered images.
Via
Investor's Business Daily
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
October 21, 2021
Cortexyme is testing a twice-day pill to treat Alzheimer's disease.
Via
Investor's Business Daily
10 Biggest Price Target Changes For Thursday
October 21, 2021
Wedbush boosted Tesla, Inc. (NASDAQ:TSLA) price ...
Via
Benzinga
Biogen inc (BIIB) Q3 2021 Earnings Call Transcript
October 20, 2021
BIIB earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
October 20, 2021
Just before Tuesday’s close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company...
Via
Benzinga
Biogen CEO Says Alzheimer's Uptake 'Is Delayed,' But Shares Pop On Earnings Beat
October 20, 2021
Biogen's Alzheimer's drug is facing delayed uptake, but Q3 sales and earnings beat.
Via
Investor's Business Daily
Biogen Posts Just $300K Sales From Aduhelm In Q3, Though Earnings Beat Estimates
October 20, 2021
Biogen Inc (NASDAQ: BIIB) has posted Q3 adjusted EPS of $4.77 ahead of the consensus estimate of $4.11, but quarterly profit fell around 53% Y/Y to $329.2 million...
Via
Benzinga
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
October 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19...
Via
Benzinga
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.